DDX53 and neoplasm: Even though anti-PD-1 therapy as a single agent showed a strong trend toward delaying tumor growth regardless of the anatomic site of the tumor (Supplementary Figure S5A), the combination of anti-PD-1 with either CBL0137 HAI or 5FU HAI did not improve survival compared to anti-PD-1 alone in the CT26 model (Figure 7A).